SecuritySGX:U11 / United Overseas Bank Ltd
Institutional Owners0

Institutional Stock Ownership and Shareholders

United Overseas Bank Ltd (SGX:U11) has 0 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). Largest shareholders include .
United Overseas Bank Ltd (SGX:U11) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Important Note!
Note: We do not currently have a CUSIP on file for this security. That means we are unable to search institutional fund filings (13F's) for this company, which means there may be institutional holders that we are unaware of. If you know the CUSIP or would like us to research and update this security, please let us know by leaving a message in the Welcome Group.
File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

UOB named Best Regional Bank of the Year for Belt and Road Initiative in Southeast Asia

11h theedgemarkets
SINGAPORE (Sept 19): United Overseas Bank (UOB) has been named Best Regional Bank of the Year for the Belt and Road Initiative (BRI) in Southeast Asia at the 2018 Asiamoney New Silk Road Finance Awards.

The State of the Nation: Slower export growth ahead on external uncertainties

2018-09-17 theedgemarkets
EXPORT growth in July came as a surprise to everyone, beating consensus estimate of 4.7% to register 9.4% year on year. This came on the back of higher electrical and electronic (E&E) exports and a slower drop in commodity exports.

Public Bank among the most expensive in the region

2018-09-14 thestar.com.my
High returns: Public Bank, which is 22.8-owned by Teh, is trading at 2.45 times its book value. (5-0)

Fresh push for banking M&As

2018-09-14 thestar.com.my
TWO decades since the 1997/98 Asian Financial Crisis (AFC), the regional banking landscape has changed much, especially in the last few years with the emergence of online and mobile banks, as well as peer-to-peer lending and payment practices.

Most rise as trade war fears ease; Thailand sees best week in 6 months

2018-09-14 theedgemarkets
(Sept 14): Most Southeast Asian stock markets rose on Friday, with Thai shares posting their best weekly gain since mid-March, as trade worries eased after China welcomed an invitation from the United States for a new round of talks.